A beneficial deal

31/08/24 -"We have integrated the recent figures, which were broadly in line with our expectations. The positive from the out-licencing of the most advanced pipeline assets (all the mRNA vaccine candidates ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

31/08/24

Download

You may also be interested by these reports :

28/11/25

NOVO NORDISK

Novo’s investors losing more weight than its patients

25/11/25

CureVac

CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...

25/11/25

Novo Nordisk

Even though the sentiment around Novo has been extremely adverse (further exacerbated by today’s R&D development around Alzheimer’s), in our opinion, ...

21/11/25

Sandoz

Ever since Sandoz demerged from Novartis, the generics/biosimilars giant has been delivering on its promises, and remains well on track to achieve ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue